Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419336 | 1.00 | POLB (0.67) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL3500223 | 0.84 | MKNK1 (0.55) | POLBHCAR2KDM4EALDH1A1MEN1 | |
| SCHEMBL22569116 | 0.82 | HTT (0.78) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL3711195 | 0.81 | RAB9A (0.53) | POLBHCAR2KDM4EHTTRAB9A | |
| Ethane SCHEMBL28837432 | 0.81 | HCAR2 (0.92) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL112388 | 0.80 | HCAR2 (1.00) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL29603529 | 0.80 | HCAR2 (1.00) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL28801075 | 0.80 | POLB (0.69) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL6564351 | 0.79 | POLB (0.62) | POLBHCAR2KDM4EHTTRAB9A | |
| SCHEMBL29433500 | 0.79 | POLB (0.62) | POLBHCAR2KDM4EHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110204548-B | Pyridazino triazole medicine molecule with sterilization and disinfection effects and preparation method and application thereof | 河南科技大学第一附属医院 | 2020-05-12 | — | — | CN | claimed |
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025215303-A1 | SULFONAMIDES, COMPOSITIONS COMPRISING SAID SULFONAMIDES, METHODS FOR THE PREPARATION OF SAID SULFONAMIDES, AND SAID SULFONAMIDES FOR USE AS MEDICAMENT AND IN A METHOD FOR THE TREATMENT OR PREVENTION OF AN OCULAR DISEASE OR CONDITION, OR IDIOPATHIC INTRACRANIAL HYPERTENSION | ITÄ-SUOMEN YLIOPISTO (FI) | 2025-10-16 | — | — | WO | disclosed |
| US-12428411-B2 | Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250250266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| WO-2003027101-A1 | SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1995028400-A1 | NOVEL BENZOFUSED 5-MEMBERED HETEROCYCLIC RINGS FOR THE TREATMENT OF MIGRAINE | GLAXO GROUP LIMITED (GB) | 1995-10-26 | — | — | WO | disclosed |
| US-5026702-A | Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins | DR. KARL THOMAE, GMBH (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0334146-A1 | Morpholines and morpholine-N-oxides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | POLB 404/4885HCAR2 2258/4885KDM4E 1159/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | POLB 1471/4885HCAR2 3697/4885KDM4E 2983/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | POLB 4023/4885HCAR2 64/4885KDM4E 1807/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | POLB 3946/4885HCAR2 3151/4885KDM4E 2732/4885 |
| US-12428411-B2 | Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | DGAT2, DGAT1, MOGAT2 | POLB 4575/4885HCAR2 1081/4885KDM4E 2199/4885 |
| US-20250250266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | POLB 654/4885HCAR2 4221/4885KDM4E 1589/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | POLB 4373/4885HCAR2 33/4885KDM4E 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.